Tag:
hemophilia
Latest Headlines
Latest Headlines
Sangamo spikes on $13M discovery pact with Shire
Shares of Sangamo BioSciences spiked 22% this morning after the Richmond, CA-based biotech announced plans to team up with Shire on a discovery pact to find new treatments for hemophilia and other
Biogen CEO Scangos aims to patch weak points in pipeline
After two years of sweeping change at Biogen Idec ( $BIIB ), CEO George Scangos ( photo ) and his team have some work to do on plugging some of the holes in the company's early-stage pipeline, from which
UPDATED: Ipsen-backed Inspiration Biopharma leaving California for Boston area
Score one for the Boston-area biotech scene. With a newly appointed chief executive from Genzyme, Inspiration Biopharmaceuticals is relocating from Laguna Niguel, CA, to the biotech-rich Kendall
Ipsen plans new hires, $45M R&D expansion as it relocates U.S. HQ
Paris-based Ipsen is reorganizing its U.S. operations, shifting its American headquarters from California to New Jersey, hiring 100 employees and investing $45 million in an upgrade of its R&D
Gene therapy study offers proof of potential breakthrough on hemophilia
A transatlantic team of investigators has presented some promising--though very early stage--breakthrough data on a new gene therapy for hemophilia B. The investigators say that their gene therapy
Discovery reveals possible way to engineer blood vessels to deliver drugs
Children's Hospital Boston researchers believe they have may have found a way to genetically engineer blood vessels to secrete recombinant, protein-based drugs directly into the bloodstream--on...
Inspiration nabs $35M milestone on EMA hemophilia review
The EMA has accepted Inspiration Biopharmaceuticals' marketing app for its new treatment for hemophilia B, triggering a $35 million milestone payment from its European partner Ipsen. The French
Maxygen inks $120M deal for hemophilia program
Maxygen has inked a deal to sell its hemophilia drug development program to Bayer for $90 million upfront and up to $30 million in milestone payments. The program is still in the preclinical stage,
